Company Overview
Sarepta Therapeutics, Inc. operates as a commercial-stage biopharmaceutical company dedicated to the discovery and development of RNA-targeted therapeutics, including siRNA platforms, gene therapy, and other genetic therapeutic modalities designed for the treatment of rare diseases. The company functions within the Healthcare sector and the Biotechnology industry, positions that define its focus on specialized, high-cost medical interventions rather than mass-market pharmaceuticals. Currently, the organization employs 835 individuals and holds a market capitalization of $1.75B while generating annual revenue of $2.20B. These valuation and revenue figures indicate that the company maintains a significant position within the biotechnology landscape, reflecting substantial market confidence despite the inherent risks associated with its developmental stage.
Financial Health
The company reported revenue of $2.20B over the trailing twelve months, yet recorded a net income of $-713,409,984 and an EBITDA of $-613,251,008. The substantial gap between the positive revenue figure and the deeply negative net income reveals a cost structure where operational expenses, likely driven by research and development and manufacturing costs, significantly exceed the revenue generated. Despite the negative earnings, the company maintains a free cash flow of $95.92M, which provides a degree of financial flexibility by allowing the organization to fund operations and potentially invest in new projects without immediate reliance on external capital. The gross margin stands at -7.4%, indicating that the cost of goods sold exceeds revenue, a common challenge in early-stage biotechnology scaling. The operating margin is -92.6%, and the profit margin is -32.5%, both negative figures that highlight the intense pressure on profitability before the company achieves widespread commercial success. On the balance sheet, the company holds $939.65M in cash against $1.04B in debt, resulting in a debt-to-equity ratio of 91.14, which suggests a leveraged balance sheet where liabilities approach the level of equity. The current ratio is 2.32, a metric that indicates the company possesses sufficient short-term assets to cover its short-term liabilities, ensuring adequate liquidity for immediate obligations. Finally, the return on equity is -53.5% and the return on assets is -11.2%, metrics that reveal that management is currently utilizing shareholder capital and company assets to generate losses rather than profits.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is 6.02, a disparity that implies the market is pricing in a future trajectory where the company expects to generate substantial positive earnings in the coming periods. The price-to-book ratio is 1.54, suggesting that the market values the company at 1.54 times its book value, which indicates a premium over the accounting value of its assets. Additionally, the price-to-sales ratio is 0.80 and the EV/EBITDA is -3.02; these alternative valuation metrics suggest that the company is being valued relative to its sales volume rather than earnings, a standard practice for firms with negative profitability. The stock has traded between a 52-week high of $76.67 and a 52-week low of $10.42, providing a wide range of historical volatility for investors to analyze. The beta value is 0.46, which means the stock is significantly less volatile than the broader market, moving with only about 46% of the intensity of the overall index.
Growth & Income
The revenue growth year-over-year is -32.7%, while the earnings growth year-over-year is N/A because the company is not currently profitable. Since earnings growth is not calculable against a positive baseline, the negative revenue growth indicates a contraction in sales, and the inability to generate earnings implies that the company has not yet reached a stage where earnings growth can be measured against revenue growth. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the organization reinvests all available earnings and cash reserves back into research, development, and operational expansion rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology firms prioritizing pipeline development over immediate shareholder returns. Overall, the company presents a growth and income profile characterized by significant revenue contraction and zero current income distribution, focusing entirely on future potential rather than current financial returns.